0g(as-4971/90/7506-0020$3.00/0 occurred upon in vitro incubation of these cells with rGM-CSF. The protective activity of rGM-CSF was examined in mice injected with Salmonella typhimurium. There was a 44-and 9-fold increase in the number of S typhimurium at 96 hours postinfection in the spleen and liver, respectively, of control mice, as compared with rGM-CSFtreated mice, after a single injection of the bacteria (3 x lo7 per mouse). All the untreated control mice died within 14 days postinoculation (1 x lo7 bacteria per mouse), whereas 35% of the mice treated with rGM-CSF remained alive for more than 30 days postinfection. These findings support the concept that increased granulopoiesis and enhanced functional activity of phagocytic cells is induced by rGM-CSF and is responsible for enhanced resistance of BMT mice to bacterial infection. 0 1990 by The American Society of Hematology.
bloodstream but may also enhance the ability of the cells to degrade microorganisms.
Various reports suggest that administration of rGM-CSF diminishes the incidence of sepsis in patients wity myelosuppression or myelody~plasia,4.'~ and Mayer et a12 have shown that the administration of rGM-CSF to nonhuman primates potentiates circulating granulocytes in their enhanced oxidative metabolism and killing (in vitro) of Escherichia coli.
In the present study, we confirm that rGM-CSF in vivo is a powerful stimulator of myelopoiesis in BMT mice and that a significant increase in 0,-generation occurs in neutrophils isolated from BMT mice given rGM-CSF. We also add two new observations. First, 48 hours and 96 hours after intraperitoneal injection with Salmonella typhimurium, BMT mice treated with rGM-CSF developed a lower incidence of bacteria in the spleen and liver than did control mice. Second, BMT mice treated with rGM-CSF also showed enhanced survival after bacterial infection. These observations suggest the possible use of rGM-CSF to diminish morbidity and mortality of such infections as those associated with myelosuppressive chemotherapy.
MATERIALS AND METHODS
Mice. Inbred male BALB/c mice, 6 to 8 weeks old, were used throughout this study. All mice were kept in conventional animal facilities.
The murine rGM-CSF used in these studies was a generous gift from Dr J. J. Mermod (Glaxo, Geneva, Switzerland). The production and purification of this CSF synthesized by E coli has been described previ~usly.'~~" Ferricytochrome C (type 111) and superoxide dismutase (SOD; type I, 3000 pL/mg protein) were obtained from Sigma Chemical Co, St Louis, MO. PMA was purchased from Consolidated Midland Corp, Brewster, NY. Iscove's modified Dulbecco's medium (IMDM) was from GIBCO, Grand Island, NY. Fetal calf serum (FCS) was purchased from Hyclone Lab, Logan, UT. Host miee were placed in plastic retainers and subjected to 9.5 Gy from a 6oCo source at a dose rate of .94 Gy/min. Donor mice were sacrificed and marrow cells were flushed from femorae and tibiae with IMDM into sterile polystyrene tubes, and then dispersed into single cells by repeated aspiration through a
Reagents.
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22-gauge needle. Viable nucleated cells (1 x lo6) in 0.3 mL saline pyrogen-free were injected into the tail vein of irradiated syngeneic recipients 2 hours after irradiation.
Mice were injected intraperitoneally (IP) with 0.2 mL of diluent or saline containing 150 ng rGM-CSF twice daily at 8:OO am and 5:OO pm. The first injection was performed 24 hours after BMT. Mice were injected with rGM-CSF for 18 consecutive days.
At various times after BMT (as indicated in "Results") peripheral hlwd obtained from the retrwrbital veins of the mice was collected in heparinized (44.7 pL) capillaries and counted by a Coulter counter (model S+; Coulter Electronics, Hialeah, FL). A differential cell count (100 cells counted) was taken on a Wright-Giemsa-stained cytocentrifuge preparation from four mice per group in each of three experiments.
On day 17 post-BMT, control or rGM-CSF-treated mice were injected IP with 2 mL calcium caseinate (0.2% wt/vol in a solution of 0.168 mol/L NaCI, pH 7.2) followed by a second injection 15 hours later.'* Mice were sacrificed 3 hours after the second injection, and peritoneal cells were collected after injection of 5 mL of isotonic saline. Exudates containing a large number of contaminating erythrocytes were discarded. The peritoneal exudate cells were washed three times with phosphate-buffered saline (PBS) at 4OC. The cells were found to comprise greater than 85% neutrophils as estimated by differential counts of stained cells. Assessment of therapeutic activity of rGM-CSF to bacterial infection. The in vivo therapeutic effect of rGM-CSF was assessed in mice infected with S typhimurium on day 9 after BMT. For infection, mice were inoculated IP with 1 x lo7 or 3 x lo7 S typhimurium suspended in 0.3 mL of saline. These inocula were prepared by diluting fresh bacteria cultures with saline to an appropriate optical density. The infected mice continued to be treated with rGM-CSF or diluent according to the injection schedule, as described above. Eight mice were sacrificed 48 and 96 hours post-bacterial infection. Spleen and liver of each mouse were homogenized separately in a loose glass homogenizer. Dilutions of the homogenized tissues were seeded in trypticase soy agar (in duplicates). Plates were incubated at 37OC for 24 houm and the number of colonies was determined. The number of bacteria per organ was calculated. Results are expressed as mean f SE of two experiments containing four mice per group per experiment. The percentage of survivors relative to the total number of infected mice was determined daily.
Hematologic evaluations.
Mobilization of peritoneal neutrophils.
Assay of NADPH-dependent 0,-production. Statistical analysis. Statistical analyses were performed using the Student's t test and paired t test. Results were considered significant when P was 5.05.
RESULTS

Peripheral blood changes.
Since the ability to defend against bacterial infections is dependent on the number as well as the activity of polymorphonuclear leukocytes, a study was conducted on the ability of rGM-CSF to restore leukocyte counts in lethally irradiated mice after BMT. Peripheral blood white cell counts were performed on lethally irradiated mice after BMT, and twice daily IP injections of 150 ng rGM-CSF were given for 18 sequential days. As shown in Fig 1, a marked increase in total viable cell counts was observed in rGM-CSF-treated mice on days 8 to 18 post-BMT (at which time the experiments were terminated) as compared with control mice. On day 11 post-BMT, the level of neutrophils in control and rGM-CSF treated mice was 1.12 f 0.1 versus 2.17 f 0.2 x 109/L, respectively. The 2.5-fold elevation in leukocyte counts observed on day 15 post-BMT resulted from a fourfold elevation in neutrophil levels, the only significant change observed. No significant effect was observed on the number of eosinophils or monocytes in the blood (data not shown).
Effect of rGM-CSF on the number and function of peritoneal neutrophils. BMT mice were injected twice daily with 150 ng rGM-CSF or diluent for 18 days. On day 17 the mice were injected with 2 mL calcium caseinate. Three hours after the second injection (on day 18) the number and function of the peritoneal mobilized neutrophils were determined. The average neutrophil count per mouse was 119.5 x lo5 and 68.3 x lo5 for rGM-CSF and control mice, respectively (mean f SE of four experiments, five mice per group in each experiment).
Assays were performed on the ability of peritoneal mobilized neutrophils to produce 0,-in response to suboptimal concentrations of PMA (5 nmol/L). As can be seen in Fig 2, For Effect of rGM-CSF on bacterial infection in BMT mice. The protective activity of rGM-CSF was examined in BMT mice infected with various doses of S typhimurim. In these experiments a single IP injection of 1 x IO7 or 3 x IO7 S typhimurium was given on the ninth day after BMT. rGM-CSF or diluent were injected twice daily according to the schedule.
As can be seen in Table 1 , at both challenge doses (1 x lo7 and 3 x lo7 bacteria), mice receiving rGM-CSF showed enhanced antibacterial resistance. At 48 hours postinfection with 3 x 1 O7 bacteria per mouse, an 1 1 -and 14-fold increase in the number of S typhimurium developed in the spleen and liver, respectively, of control mice as compared with rGM-CSF-treated mice. The protective effect of rGM-CSF could be observed also 96 hours postinfection (with the higher challenge dose), at which time a 44-and 9-fold increase in the number of bacteria developed in the spleen and liver of control versus rGM-CSF-treated mice.
rGM-CSF showed a protective effect against infections induced by S typhimurium (Fig 3) . At the lower challenge dose of bacteria, all infected mice died within 14 days postinfection, while 35% of rGM-CSF-treated mice survived over 30 days. With the higher challenge dose, 10% of rGM-CSF-treated mice survived over 30 days, while all control mice died within 8 days postinfection.
DISCUSSION
The findings of our study demonstrate that rGM-CSF is a potent inducer of antibacterial resistance in bone marrow transplanted mice. This enhanced resistance was paralleled by increases in the number of circulating neutrophils in the peripheral blood, as well as in the overall pool of neutrophils Days a f t e r infection in the body, as demonstrated by the number of cells that were mobilized into the peritoneal cavity. No other changes in the peripheral blood were observed. Other studies have shown that continuous intravenous administration of human GM-CSF for several days after BMT results in accelerated granulocyte r e c~v e r y . l~~~~~'~ Our observations are in agreement with the findings of Metcalf et a1," who have reported that intraperitoneal injection of recombinant murine GM-CSF into normal mice for several days results in a twofold elevation of neutrophil levels, while no other changes in the peripheral blood were observed.
GM-CSF ENHANCES RESISTANCE TO BACTERIAL INFECTIONS
Neutrophils are essential for host defense against microbial infections. A drop in their number or functional activity may lead to severe Recently, GM-CSF has been used to shorten the period of neutropenia after autologous BMT,'s3s6 to promote hematopoietic recovery after cytotoxic chemotherapy2' in patients with malignan~y?~ and to enhance neutrophil function in acquired immunodeficiency syndrome patients.24 Our study shows that neutrophils of BMT mice treated in vivo with rGM-CSF are primed for enhanced superoxide release when stimulated with PMA. This finding is in agreement with results reported by Kaplan et all' and Sullivan et all' in preliminary human clinical trials, and by Welte et a125 in studies conducted on monkeys.
In primates treated with rGM-CSF, Mayer et a12 obtained enhanced oxidative metabolism and also a toxic effect on an E coli strain as assessed in vitro. To the best of our knowledge, ours is the first report on the effect of rGM-CSF on the development of a bacterial infection in BMT mice and on host resistance to microbial infections. It should be noted that Minami et alZ6 and McIntyre et a127 have recently found that interleukin-1 enhances antibacterial resistance in mice. Also, Cohen et a12' have reported on resistance of neutropenic hamsters to bacterial infections after their daily dosing with recombinant human granulocyte colony-stimulating factor (G-CSF), while Matsumoto et a129 found that in neutropenic mice subjected to intraperitoneal infection with bacteria or yeasts, G-CSF exerted a protective effect against systemic infections with these microorganisms.
In vivo studies have indicated that intraperitoneal injection of rGM-CSF into mice results in a rise in peritoneal macrophages, eosinophils, and neutrophils, and that the peritoneal macrophages were larger than resting macrophages and exhibited cytoplasmic vacuolation and increased phagocytic capacity. 21 In a previous study, we have shown that rGM-CSF can enhance intracellular killing of microorganisms by murine macrophage^.^' Our present data suggest that rGM-CSF increases leukocyte count in BMT mice, primes peritoneal neutrophils for enhanced 0,-release, and contributes importantly to the enhancement of the resistance of BMT mice to bacteria. Although the effects of injected rGM-CSF cannot be proved to be direct on neutrophils, macrophages, or other leukocytes, and might in part have been due to interactions with other factors or indirect effects, our findings indicate that rGM-CSF could be efficacious in limiting the duration of neutropenia and possibly also in mitigating the risk of the development of bacterial infections associated with bone marrow suppression. 
